论文部分内容阅读
摘自《医学参考报营养学频道》2014年8月第8期【据《JPEN J Parenter Enteral Nutr》2014年4月报道】题:A.S.P.E.N.临床指南:具有肠外营养相关性肝病风险的儿科肠衰竭患者的支持指南(作者Wales PW等)肠外营养相关肝疾病(PNALD)也叫肠衰竭相关肝损害(intestinal failure associated liver disease,IFALD),是一种由长期肠外营养产生的严重的可危及生命的并发症。PNALD由多种因素导致。肠外营养的所有成分都可能促进胆汁淤积。北美使用的大部分肠外营养制剂均采用大豆脂肪乳剂。大豆脂肪乳中被认为会促进胆汁淤积的成分主要是ω-6长链多不饱和脂肪酸、植物甾醇和较低的抗氧化物含量。
From “Medical Reference Newsletters” August 2014 Issue 8 [According to “JPEN J Parenter Enteral Nutr” April 2014 report] Title: ASPEN Clinical Guideline: Patients with Pediatric Intestinal Failure at Risk of Parenteral Nutrition-Related Liver Disease (By PW PW, et al) Parenteral nutrition-related liver disease (PNALD), also known as intestinal failure associated liver disease (IFALD), is a serious, life-threatening, long-term parenteral nutrition Complications. PNALD is caused by many factors. All components of parenteral nutrition may promote cholestasis. Most parenteral nutrition formulations used in North America are based on soy fat emulsions. The components of soya fat emulsion that are thought to promote cholestasis are mainly omega-6 long-chain polyunsaturated fatty acids, phytosterols and lower antioxidants.